Michael Listgarten
Conseiller Juridique Général chez RAPT THERAPEUTICS, INC.
Profil
Michael Listgarten is currently working as the General Counsel at Rapt Therapeutics, Inc. He previously held positions as the Vice President-Healthcare Law at Principia Biopharma, Inc. and as the VP-Healthcare Law & Chief Compliance Officer at Adamas Pharmaceuticals LLC.
Mr. Listgarten has a graduate degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from the University of Pennsylvania.
Postes actifs de Michael Listgarten
| Sociétés | Poste | Début |
|---|---|---|
| RAPT THERAPEUTICS, INC. | Conseiller Juridique Général | 03/05/2023 |
Anciens postes connus de Michael Listgarten
| Sociétés | Poste | Fin |
|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Compliance Officer | 01/11/2021 |
| PRINCIPIA BIOPHARMA INC. | Corporate Officer/Principal | 01/12/2020 |
Formation de Michael Listgarten
| University of Pennsylvania | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| RAPT THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |